The full abstract will be published online on April 25, 2025. More details about the programs for the AACR Annual Meeting 2025 are available online at AACR Annual Meeting 2025 | Meetings | AACR.

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared ...

Clinical data supporting mechanism of action reinforce potential as a novel cancer treatmentBRISBANE, Calif., March 25, 2025 ...

Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC –– Company expects to present data ...

Relmada Therapeutics pivots to NDV-01 for bladder cancer & Sepranolone for Tourette's. Phase 2 results expected April 2025.

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

Jessica Adsit, MS, CGC is the 2025 recipient of the. The ACMG Foundation for Genetic and Genomic Medicine presented Ms. Adsit this award for her platform presentation, “Next Generation Sequencing in ...

Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients ...

Louise Bourgeois, Eva Hesse, Alice Adams is the first exhibition to bring together sculpture by three pioneering artists of the 20th century ...

Ifetroban demonstrated significant 5.4% improvement in cardiac functionNASHVILLE, Tenn., March 19, 2025 /PRNewswire/ -- Cumberland Pharma ...